Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-11-26 Major Shareholding Noti…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
关于控股股东、实际控制人及一致行动人权益变动触及5%整倍数的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in shareholding percentages involving the controlling shareholder and related parties. It details the reduction in shares held by a significant shareholder and the resulting impact on ownership percentages. The document includes specific dates, share quantities, and confirms compliance with relevant securities laws. It is a typical major shareholding notification, as it reports a change in significant share ownership levels crossing a 5% threshold. The document is not a full financial report, earnings release, or management discussion, nor is it an announcement of a report publication. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2025-11-26 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the reduction in shareholding by the information disclosure obligor and their related parties, including specific share counts and percentages before and after the change. It references relevant securities laws and stock exchange rules, and includes declarations about the accuracy and completeness of the information. The document is focused on reporting changes in significant share ownership and related disclosures. There is no indication of financial statements, earnings data, management discussion, or other report types. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2025-11-26 Chinese
独立董事专门会议关于2024年股权激励计划首次授予限制性股票第一个解除限售期解除限售条件成就事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Chengdu Oukang Pharmaceutical Co., Ltd. regarding the verification opinion of the independent directors' special meeting on the achievement of conditions for the first lifting of restrictions on restricted stocks granted under the 2024 equity incentive plan. It discusses compliance with relevant laws and regulations, performance assessments, and confirms that the conditions for lifting restrictions have been met. The document is short (764 characters) and is an announcement about a specific corporate governance event related to equity incentive plans, not a full report or financial statement. It does not contain financial data or detailed management discussion but is a regulatory announcement about a corporate action related to stock incentives. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-11-17 Chinese
第四届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the 4th Board of Directors of Chengdu Oukang Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references related regulatory compliance and company law. The content focuses on board decisions, specifically about the 2024 equity incentive plan and related stock release conditions. There is no financial data, earnings information, or detailed report content. The document is clearly a Board/Management Information announcement about board meeting resolutions and decisions, not a full report or financial statement.
2025-11-17 Chinese
关于2024年股权激励计划首次授予限制性股票第一个解除限售期解限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Chengdu Oukang Pharmaceutical Co., Ltd. regarding the achievement of the first unlocking condition of restricted shares granted under the 2024 equity incentive plan. It details the decision-making process, performance conditions, individual and company-level performance assessments, and the number of shares eligible for unlocking. The document includes legal opinions and independent director reviews confirming the unlocking conditions have been met. It is a formal disclosure about the status and progress of a stock-based incentive plan, specifically about the lifting of restrictions on shares granted to employees and executives. This type of document is best classified as a Regulatory Filing (RNS) because it is an announcement of a corporate event related to equity incentives and share restrictions being lifted, rather than a full financial report, earnings release, or other specific report type. It is not a report publication announcement since it contains substantive details and legal opinions, nor is it a remuneration report or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-11-17 Chinese
北京德恒（重庆）律师事务所关于成都欧康医药股份有限公司2024年股权激励计划首次授予部分第一个解除限售期解除限售条件成就的法律意见
Regulatory Filings Classification · 27% confidence The document is a legal opinion provided by Beijing Deheng (Chongqing) Law Firm concerning the unlocking of restricted shares under Chengdu Okang Pharmaceutical Co., Ltd.’s 2024 equity incentive plan. It is not itself a financial statement, earnings release, proxy solicitation, or any specific regulated corporate filing category but rather a legal memorandum/opinion. Therefore it best fits the fallback category for miscellaneous regulatory filings.
2025-11-17 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.